A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers

NCT00863590 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: odanacatib
DRUG: Comparator: odanacatib (Panel B)
DRUG: Comparator: odanacatib (Panel C)
DRUG: Comparator: odanacatib (Panel D)

Sponsor

Merck Sharp & Dohme LLC